Everest Clinical Research Expands Global Biometrics Capabilities with Acquisition of Firma Clinical Research’s Data Services Business Unit

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Everest Clinical Research Expands Global Biometrics Capabilities with Acquisition of Firma Clinical Research's Data Services Business UnitAuthor of the article:THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountTORONTO — Everest Clinical Research (“Everest”), a data-first, full-service clinical research organization, today announced the acquisition of the Biometrics and Data Services business unit of Firma Clinical Research (“Firma DS”), expanding Everest’s global biometrics expertise and clinical data science capabilities. Everest is a portfolio company of Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private equity firm with extensive experience investing in regulated industries.Firma DS provides biometrics and clinical data services to biotechnology, pharmaceutical, medical device, and diagnostic companies, delivering high-quality support across the clinical development lifecycle. The business unit has supported more than 1,000 clinical studies and over 60 New Drug Application (NDA) submissions across complex therapeutic areas including oncology, neurology, rare disease, hepatology, and nephrology.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try again“This acquisition reflects our continued investment in exceptional clinical data science talent and reinforces our commitment to helping clients bring therapies to patients faster,” said Jin Dai, Chief Executive Officer of Everest. “From our earliest conversations, it was clear that the Firma DS team shares our commitment to high-quality delivery with flexibility, responsiveness and speed. Together, we are expanding our ability to support sponsors with increasingly complex clinical development programs around the world.”As part of the acquisition, an experienced team of biometrics professionals will join Everest’s global organization, strengthening the company’s delivery capabilities across the US and the Asia-Pacific regions where clinical development activity continues to grow.“We are delighted to welcome these talented professionals to Everest,” said Rob Woolson, Chief Operating Officer of Everest. “By combining our collective expertise, we can deliver even greater value to sponsors navigating increasingly complex development programs. Throughout the transition, maintaining team continuity and seamless service for Firma DS clients remains our highest priority.”Existing Firma DS clients will gain access to Everest’s global delivery infrastructure and scale, advanced technology platforms, and full-service clinical development capabilities, including regulatory strategy, clinical operations, clinical trial technologies, medical affairs, patient safety, and medical writing—through a single global CRO partner.“As clinical development grows more global and complex, sponsors need partners with the scale, expertise, and integrated capabilities to support programs across geographies and regulatory environments,” said Malcolm Little, a partner at Arlington Capital Partners. “This acquisition strengthens Everest’s ability to meet that need and support clients worldwide.”About Everest Clinical Research Everest Clinical Research is a data-first, full-service contract research organization (CRO) providing comprehensive clinical development services to pharmaceutical, biotechnology, and medical device companies worldwide. By integrating industry-leading biometrics expertise with end-to-end clinical development services, Everest helps sponsors navigate complex clinical trials with scientific rigor, operational excellence, and personalized client service. With global operations across North America, Asia-Pacific, and Europe, Everest partners with clients to accelerate the development of innovative therapies for patients around the world. For more information, visitView source version on businesswire.com: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.